Current Liabilities decreased faster than Gracell Biotechnologies Inc 's Cash & cash equivalent, this led to improvement in Gracell Biotechnologies Inc 's Quick Ratio to 6.58, Quick Ratio remained below Gracell Biotechnologies Inc average.

Within Major Pharmaceutical Preparations industry 209 other companies have achieved higher Quick Ratio than Gracell Biotechnologies Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 621 to 922.

Explain Quick Ratio?
How much Cash & cash equivalents GRCL�s has?
What are GRCL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GRCL/financial-strength

https://api.csimarket.com/api/v1/companies/GRCL/fundamentals

https://api.csimarket.com/api/v1/companies/GRCL/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GRCL Quick Ratio	(Jun 30 2023) Q4	(Dec 31 2022) Q3	0 Q2	0 Q1	0 Q4
Y / Y Current Liabilities Change	-22.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-22.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	6.58	Subscribe	Subscribe	Subscribe	Subscribe
GRCL's Total Ranking	# 922	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-47.23 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-22.51 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 210
Healthcare Sector	# 364
Overall Market	# 922

Quick Ratio Statistics
High	Average	Low
13.95	8.4	4.48
(Dec 31 2019)		(Dec 31 2022)

Financial Statements
Gracell Biotechnologies Inc 's Current Liabilities	$ 25 Millions	Visit GRCL's Balance sheet
Gracell Biotechnologies Inc 's Cash & cash equivalent	$ 164 Millions	Visit GRCL's Balance sheet
Source of GRCL's Sales		Visit GRCL's Sales by Geography

Cumulative Gracell Biotechnologies Inc 's Quick Ratio

GRCL's Quick Ratio for the trailling 12 Months

GRCL Quick Ratio	(Jun 30 2023) 12 Months	(Dec 31 2022) 12 Months	0 12 Months	0 12 Months	0 12 Months
Y / Y Current Liabilities TTM Growth	31.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-21.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	5.55	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4482	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-4.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-5.35 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GRCL Financial Strength Comparisons >> Go to Compare GRCL Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in GRCL's Current Liabilities to $24.89 millions, cumulative Quick Ratio to 5.55 below the GRCL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 592 other companies have achieved higher Quick Ratio than Gracell Biotechnologies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4255 to 4482.

Explain Quick Ratio?
How much Cash & cash equivalents GRCL�s has?
What are GRCL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 593
Healthcare Sector	# 1175
Within the Market	# 4482

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.79	9.19	6.59
(Dec 31 2021)		(Dec 31 2022)

Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2023 MRQ Cash & cash equivalent	Jun 30 2023 MRQ Current Liabilities
Day One Biopharmaceuticals Inc	18.07	$ 442.882 Millions	$ 24.512 Millions
Prelude Therapeutics Inc	17.89	$ 254.989 Millions	$ 14.252 Millions
Savara Inc	17.87	$ 105.179 Millions	$ 5.885 Millions
Lyell Immunopharma Inc	17.32	$ 595.748 Millions	$ 34.390 Millions
Kezar Life Sciences Inc	17.22	$ 236.589 Millions	$ 13.737 Millions
Agios Pharmaceuticals Inc	17.21	$ 702.566 Millions	$ 40.815 Millions
Rallybio Corporation	17.12	$ 137.838 Millions	$ 8.053 Millions
Janux Therapeutics Inc	16.94	$ 303.289 Millions	$ 17.904 Millions
Shuttle Pharmaceuticals Holdings Inc	16.92	$ 8.351 Millions	$ 0.494 Millions
Ventyx Biosciences Inc	16.58	$ 332.252 Millions	$ 20.034 Millions
Cymabay Therapeutics Inc	16.38	$ 213.844 Millions	$ 13.056 Millions
Pmv Pharmaceuticals Inc	16.34	$ 187.087 Millions	$ 11.447 Millions
Mineralys Therapeutics Inc	16.29	$ 101.140 Millions	$ 6.207 Millions
Tenax Therapeutics Inc	16.26	$ 13.394 Millions	$ 0.824 Millions
Scpharmaceuticals Inc	16.16	$ 102.877 Millions	$ 6.368 Millions
Lantern Pharma Inc	15.90	$ 47.949 Millions	$ 3.016 Millions
Biomea Fusion Inc	15.53	$ 222.908 Millions	$ 14.357 Millions
Pyxis Oncology Inc	15.46	$ 142.663 Millions	$ 9.225 Millions
Nanoviricides inc	15.25	$ 8.150 Millions	$ 0.534 Millions
Dynavax Technologies Corporation	15.19	$ 681.525 Millions	$ 44.862 Millions
Landos Biopharma Inc	14.84	$ 44.736 Millions	$ 3.015 Millions
Sensei Biotherapeutics Inc	14.72	$ 78.840 Millions	$ 5.357 Millions
Eledon Pharmaceuticals Inc	14.57	$ 71.378 Millions	$ 4.900 Millions
Larimar Therapeutics Inc	14.32	$ 104.200 Millions	$ 7.275 Millions
Lipocine Inc	14.11	$ 25.790 Millions	$ 1.827 Millions
Verve Therapeutics Inc	14.00	$ 462.476 Millions	$ 33.031 Millions
Anixa Biosciences Inc	13.75	$ 25.534 Millions	$ 1.857 Millions
Artelo Biosciences Inc	13.72	$ 8.272 Millions	$ 0.603 Millions
Dianthus Therapeutics Inc	13.69	$ 55.240 Millions	$ 4.034 Millions
Erasca Inc	13.62	$ 317.245 Millions	$ 23.292 Millions

Date modified: 2026-09-08T15:10:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.